# RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

Source: https://onco.cc/trials/nct05966194/  
OnCo record `nct05966194` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cisplatin in head and neck squamous cell carcinoma, run by EpicentRx, Inc., active and no longer recruiting.

## Summary

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer is a phase 2 interventional study registered as NCT05966194 by EpicentRx, Inc., with 216 participants enrolled, started 2024-04-02 and due to reach its primary completion in 2027-07-01. Interventions recorded: RRx-001, Intensity Modulated Radiation Therapy (IMRT) and Cisplatin for injection 100 mg/m2.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05966194
- Phase: 2
- Setting: A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
- Sponsor: EpicentRx, Inc.
- Enrolled: 216

## Sources

- ClinicalTrials.gov NCT05966194: https://clinicaltrials.gov/study/NCT05966194

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/)
- companies: [EpicentRx](https://onco.cc/companies/epicentrx/)

---
JSON: https://onco.cc/api/v1/entities/nct05966194.json